Stocks · Health care · Pharmaceutical Preparations

Regeneron Pharmaceuticals

REGN Clue Score51
United States Fiscal year ends December CIK 0000872589 Results filed 30 Oct 2026

What the insiders did Scheduled selling only

Insider
Date
Role
Action
Shares
Price
Amount
Huda Y Zoghbi
3 Nov 2026
Director
Sold after exercise
500
$971.06
$485.53K
Huda Y Zoghbi
3 Nov 2026
Director
Sold after exercise
6,939
$970.42
$6.73M
Joseph J Larosa
2 Nov 2026
EVP General Counsel and Secret
Sold after exercise
527
$966.11
$509.14K
Joseph J Larosa
2 Nov 2026
EVP General Counsel and Secret
Sold after exercise
3,939
$965.41
$3.80M
Christine A Poon
2 Nov 2026
Director
Sold after exercise
201
$971.31
$195.23K
Christine A Poon
2 Nov 2026
Director
Sold after exercise
937
$970.51
$909.37K
Christine A Poon
2 Nov 2026
Director
Sold after exercise
3,203
$969.50
$3.11M
Christine A Poon
2 Nov 2026
Director
Sold after exercise
2,499
$968.58
$2.42M
Christine A Poon
2 Nov 2026
Director
Sold after exercise
772
$967.38
$746.82K
Christine A Poon
2 Nov 2026
Director
Sold after exercise
218
$966.74
$210.75K
George L Sing
2 Nov 2026
Director
Sold after exercise
200
$970.18
$194.04K
George L Sing
2 Nov 2026
Director
Sold after exercise
1,040
$967.07
$1.01M
George L Sing
2 Nov 2026
Director
Sold after exercise
1,522
$966.27
$1.47M
George L Sing
2 Nov 2026
Director
Sold after exercise
7,073
$965.38
$6.83M
George L Sing
2 Nov 2026
Director
Sold after exercise
2,670
$964.57
$2.58M
George L Sing
2 Nov 2026
Director
Sold after exercise
4,338
$963.47
$4.18M
George L Sing
2 Nov 2026
Director
Sold after exercise
2,522
$962.61
$2.43M
George L Sing
2 Nov 2026
Director
Sold after exercise
540
$961.85
$519.40K
George L Sing
2 Nov 2026
Director
Sold after exercise
1,224
$960.57
$1.18M
Michael S Brown
30 Oct 2026
Director
Sold after exercise
1,929
$875.00
$1.69M
Kathryn Guarini
30 Oct 2026
Director
Sold after exercise
400
$900.00
$360.00K

What was left out

Form 4 filings counted 10
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 28
Sales straight out of an exercise 21
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 95,001
History held since 3 Oct 2006